138 related articles for article (PubMed ID: 19453292)
1. Postmarketing surveillance of serious adverse events associated with the use of rofecoxib from 1999-2002.
Bottone FG; Barry WT
Curr Med Res Opin; 2009 Jun; 25(6):1535-50. PubMed ID: 19453292
[TBL] [Abstract][Full Text] [Related]
2. Rofecoxib and cardiovascular adverse events in adjuvant treatment of colorectal cancer.
Kerr DJ; Dunn JA; Langman MJ; Smith JL; Midgley RS; Stanley A; Stokes JC; Julier P; Iveson C; Duvvuri R; McConkey CC;
N Engl J Med; 2007 Jul; 357(4):360-9. PubMed ID: 17652651
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial.
Bresalier RS; Sandler RS; Quan H; Bolognese JA; Oxenius B; Horgan K; Lines C; Riddell R; Morton D; Lanas A; Konstam MA; Baron JA;
N Engl J Med; 2005 Mar; 352(11):1092-102. PubMed ID: 15713943
[TBL] [Abstract][Full Text] [Related]
4. Factors associated with celecoxib and rofecoxib utilization.
Rawson NS; Nourjah P; Grosser SC; Graham DJ
Ann Pharmacother; 2005 Apr; 39(4):597-602. PubMed ID: 15755796
[TBL] [Abstract][Full Text] [Related]
5. Changes in physicians' practice of prescribing cyclooxygenase-2 inhibitor after market withdrawal of rofecoxib: a retrospective study of physician-patient pairs in Taiwan.
Hsiao FY; Tsai YW; Huang WF
Clin Ther; 2009 Nov; 31(11):2618-27. PubMed ID: 20110006
[TBL] [Abstract][Full Text] [Related]
6. Thromboembolic cardiovascular risk among arthritis patients using cyclooxygenase-2-selective inhibitor or nonselective cyclooxygenase inhibitor nonsteroidal anti-inflammatory drugs.
Spalding WM; Reeves MJ; Whelton A
Am J Ther; 2007; 14(1):3-12. PubMed ID: 17303969
[TBL] [Abstract][Full Text] [Related]
7. Prescription channeling of COX-2 inhibitors and traditional nonselective nonsteroidal anti-inflammatory drugs: a population-based case-control study.
Moride Y; Ducruet T; Boivin JF; Moore N; Perreault S; Zhao S
Arthritis Res Ther; 2005; 7(2):R333-42. PubMed ID: 15743481
[TBL] [Abstract][Full Text] [Related]
8. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction.
Gislason GH; Jacobsen S; Rasmussen JN; Rasmussen S; Buch P; Friberg J; Schramm TK; Abildstrom SZ; Køber L; Madsen M; Torp-Pedersen C
Circulation; 2006 Jun; 113(25):2906-13. PubMed ID: 16785336
[TBL] [Abstract][Full Text] [Related]
9. The trade-off between cardiovascular and gastrointestinal effects of rofecoxib.
Florentinus SR; Heerdink ER; de Boer A; van Dijk L; Leufkens HG
Pharmacoepidemiol Drug Saf; 2005 Jul; 14(7):437-41. PubMed ID: 15937867
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the baseline cardiovascular risk profile among hypertensive patients prescribed COX-2-specific inhibitors or nonspecific NSAIDs: data from real-life practice.
Zhao SZ; Burke TA; Whelton A; von Allmen H; Henderson SC
Am J Manag Care; 2002 Oct; 8(15 Suppl):S392-400. PubMed ID: 12416789
[TBL] [Abstract][Full Text] [Related]
11. Association between nonnaproxen NSAIDs, COX-2 inhibitors and hospitalization for acute myocardial infarction among the elderly: a retrospective cohort study.
Rahme E; Watson DJ; Kong SX; Toubouti Y; LeLorier J
Pharmacoepidemiol Drug Saf; 2007 May; 16(5):493-503. PubMed ID: 17086567
[TBL] [Abstract][Full Text] [Related]
12. Adverse Drug Events Involving COX-2 Inhibitors.
Verrico MM; Weber RJ; McKaveney TP; Ansani NT; Towers AL
Ann Pharmacother; 2003 Sep; 37(9):1203-13. PubMed ID: 12921500
[TBL] [Abstract][Full Text] [Related]
13. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults.
Solomon DH; Schneeweiss S; Glynn RJ; Kiyota Y; Levin R; Mogun H; Avorn J
Circulation; 2004 May; 109(17):2068-73. PubMed ID: 15096449
[TBL] [Abstract][Full Text] [Related]
14. A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas.
Baron JA; Sandler RS; Bresalier RS; Quan H; Riddell R; Lanas A; Bolognese JA; Oxenius B; Horgan K; Loftus S; Morton DG;
Gastroenterology; 2006 Dec; 131(6):1674-82. PubMed ID: 17087947
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs: high-risk subgroups and time course of risk.
Solomon DH; Avorn J; Stürmer T; Glynn RJ; Mogun H; Schneeweiss S
Arthritis Rheum; 2006 May; 54(5):1378-89. PubMed ID: 16645966
[TBL] [Abstract][Full Text] [Related]
16. Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program.
Weir MR; Sperling RS; Reicin A; Gertz BJ
Am Heart J; 2003 Oct; 146(4):591-604. PubMed ID: 14564311
[TBL] [Abstract][Full Text] [Related]
17. [Use of rofecoxib in family practice in the north of Netherlands, 2000-2004: background and consequences].
van der Veen WJ; van der Werf GT
Ned Tijdschr Geneeskd; 2006 May; 150(18):1016-21. PubMed ID: 16715866
[TBL] [Abstract][Full Text] [Related]
18. Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study.
Rahme E; Nedjar H
Rheumatology (Oxford); 2007 Mar; 46(3):435-8. PubMed ID: 17255138
[TBL] [Abstract][Full Text] [Related]
19. National trends in cyclooxygenase-2 inhibitor use since market release: nonselective diffusion of a selectively cost-effective innovation.
Dai C; Stafford RS; Alexander GC
Arch Intern Med; 2005 Jan; 165(2):171-7. PubMed ID: 15668363
[TBL] [Abstract][Full Text] [Related]
20. Gastrointestinal and cardiovascular risk of non-selective NSAIDs and COX-2 inhibitors in elderly patients with knee osteoarthritis.
Turajane T; Wongbunnak R; Patcharatrakul T; Ratansumawong K; Poigampetch Y; Songpatanasilp T
J Med Assoc Thai; 2009 Dec; 92 Suppl 6():S19-26. PubMed ID: 20128070
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]